Nexalin trials Halo neurostimulation device in traumatic brain injury

By Yahoo! Finance | Oct 23, 2024 at 07:25 AM EST

Nexalin Technology and UC San Diego collaborate for a clinical trial on Gen-3 Halo headset as an at-home treatment for mild traumatic brain injury. The study aims to assess brain activity and symptom relief in veterans and could impact the neuromodulation device market.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.